Ironwood Pharmaceuticals Target of Unusually Large Options Trading (IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the recipient of some unusual options trading on Tuesday. Investors acquired 1,039 call options on the stock. This represents an increase of approximately 1,029% compared to the average daily volume of 92 call options.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 115,769 shares of company stock valued at $1,752,491 in the last quarter. Corporate insiders own 7.63% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Teacher Retirement System of Texas purchased a new stake in Ironwood Pharmaceuticals in the second quarter worth $192,000. Gerber Kawasaki Wealth & Investment Management purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth $170,000. Strs Ohio grew its stake in Ironwood Pharmaceuticals by 63.1% in the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 4,100 shares during the period. Ameritas Investment Partners Inc. grew its stake in Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 648 shares during the period. Finally, Aperio Group LLC grew its stake in Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the period.

A number of equities analysts recently commented on IRWD shares. Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $19.00 target price for the company. ValuEngine downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Mizuho downgraded Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $20.00 to $16.00 in a report on Wednesday, December 6th. Finally, BidaskClub downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $17.88.

Ironwood Pharmaceuticals (IRWD) opened at $15.39 on Friday. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. The company has a market capitalization of $2,373.62, a P/E ratio of -15.87 and a beta of 1.44. Ironwood Pharmaceuticals has a twelve month low of $13.43 and a twelve month high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The company had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm’s revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.18) earnings per share. research analysts expect that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Ironwood Pharmaceuticals Target of Unusually Large Options Trading (IRWD)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/24/ironwood-pharmaceuticals-target-of-unusually-large-options-trading-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply